JacobSandsMD

Oncology • Boston, MA

Thoracic Cancer

Physician

Join to view full profile

Dr. Sands is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sands' full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-6049

Education & Training

University of California Davis HealthFellowship, Hematology and Medical Oncology, 2009 - 2012
University of California Davis HealthResidency, Internal Medicine, 2005 - 2008
University of Cincinnati College of MedicineClass of 2005

Certifications & Licensure

FL State Medical License 2023 - Present
RI State Medical License 2023 - 2026
VT State Medical License 2023 - 2026
CT State Medical License 2023 - 2025
MA State Medical License 2012 - 2025
ME State Medical License 2023 - 2025
NH State Medical License 2023 - 2025
CA State Medical License 2006 - 2016
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients Start of enrollment: 2017 Oct 24
Completed
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2018 Dec 01
Withdrawn
Phase 2
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial Start of enrollment: 2020 Jun 16
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Myung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi
Future Oncology. 2024-11-12
Response to Crizotinib After Entrectinib Resistance in-Rearranged,-Amplified Lung Adenocarcinoma.
Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, Joao V Alessi, Arielle Elkrief
JCO Precision Oncology. 2024-10-01
2 citations
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 S...
Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard
Journal of Clinical Oncology. 2024-09-09

Journal Articles

Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous Retroviruses
Scott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature

Lectures

First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III TrialSeptember 9th, 2024
Unlocking ASCO 2024: Must-Know BreakthroughsJuly 11th, 2024
Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung CancerMay 17th, 2023
Join now to see all